Vitiligo pp 399-409 | Cite as

Depigmenting Therapies

  • Abdulrahman Aljamal
  • Mohammed Aljamal
  • Sanjeev Mulekar
  • Aleissa Ahmed


Depigmentation may be suggested when other possible treatment failed and when the lesions are perceived as disfiguring. Chemical or physical approaches are available, depending on the site and the extent of the lesions. Hydroquinone and phenol derivatives are the most appreciated chemical depigmenting agents, whereas lasers and cryotherapy may be relevant alternatives even if the last ones must be applied in hospital.


  1. 1.
    Nordlund JJ. Depigmentation for the treatment of extensive vitiligo. In: Hann SK, Nordlund JJ, editors. Vitiligo. Lucon: Blackwell Science; 2000. p. 207–13.CrossRefGoogle Scholar
  2. 2.
    Solano F, Briganti S, Picardo M, et al. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006;19:550–71.CrossRefGoogle Scholar
  3. 3.
    Alghamdi KM, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol. 2011;25:749–57.CrossRefGoogle Scholar
  4. 4.
    Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for vitiligo. J Am Acad Dermatol. 1996;35:620–6.CrossRefGoogle Scholar
  5. 5.
    Bolognia JL, Lapia BK, Somma S. Depigmentation therapy. Dermatol Ther. 2001;14:29–34.CrossRefGoogle Scholar
  6. 6.
    Van doon Boorn JG, Melief CJ, Luiten RM. Monobenzone induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res. 2011;24:673–9.CrossRefGoogle Scholar
  7. 7.
    Kim YJ, Chung BS, Choi KC. Depigmentation therapy with Q-switched ruby laser after tanning in vitiligo universalis. Dermatol Surg. 2001;27:969–70.PubMedGoogle Scholar
  8. 8.
    Lyon CC, Beck MH. Contact hypersensitivity to monobenzyl ether of hydroquinone used to treat vitiligo. Contact Dermatitis. 1998;39:132–56.CrossRefGoogle Scholar
  9. 9.
    Charlin R, Barcaui CB, Kac BK, Soares DB, Rabello Fonseca R, Azulay-Abulafia L. Hydroquinone induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. Int J Dermatol. 2008;47:19–23.CrossRefGoogle Scholar
  10. 10.
    Radmanesh M. Depigmentation of the normally pigmented patches in universal vitiligo patients by cryotherapy. J Eur Acad Dermatol Venereol. 2000;14:149–52.CrossRefGoogle Scholar
  11. 11.
    Kasraee B, Fallahi MR, Ardekani GS, Doroudchi G, Omrani GR, Handjani S, et al. Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of MBEH in black guinea pigs skin. Exp Dermatol. 2006;15:509–14.CrossRefGoogle Scholar
  12. 12.
    Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol. 2000;42:760–9.CrossRefGoogle Scholar
  13. 13.
    Zanini M. Depigmentation therapy for generalized vitiligo with topical 88% phenol solution. An Bras Dermatol. 2005;80:415–6.CrossRefGoogle Scholar
  14. 14.
    Thissen M, Westerhof W. Laser treatment for further depigmentation in vitiligo. Int J Dermatol. 1997;36:3868.CrossRefGoogle Scholar
  15. 15.
    Rao J, Fitzpatrick RE. Use of the Q-switched 755 nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg. 2004;30:1043–5.PubMedGoogle Scholar
  16. 16.
    Di Nuzzo S, Masotti A. Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole. Clin Exp Dermatol. 2010;35:215–6.CrossRefGoogle Scholar
  17. 17.
    Leong KW, Lee TC, Goh AS. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2004;100:2486–7.CrossRefGoogle Scholar
  18. 18.
    Halder RM, Taliaferro SJ. Vitiligo. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Lefell DJ, editors. Fitzpatrick’s dermatology in general medicine, vol. 1. 7th ed. New York: McGraw Hill; 2008. p. 61622.Google Scholar
  19. 19.
    Zirvi TB, Costarelis G, Gelfand JM. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol. 2005;52:715–6.CrossRefGoogle Scholar
  20. 20.
    Kang HY, Park TJ, Jin SH. Imiquimod, a toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. J Invest Dermatol. 2009;129:243–6.CrossRefGoogle Scholar
  21. 21.
    Kim CH, Ahn JH, Kang SU, Hwang HS, Lee MH, Pyun JH, et al. Imiquimod induces apoptosis of human melanocytes. Arch Dermatol Res. 2010;302:301–6.CrossRefGoogle Scholar
  22. 22.
    Senel E, Seckin D. Imiquimod-induced vitiligo-like depigmentation. Indian J Dermatol Venereol Leprol. 2007;73:422–3.CrossRefGoogle Scholar
  23. 23.
    Duhra P, Foulds IS. Persistent vitiligo induced by diphencyprone. Br J Dermatol. 1990;123:415–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Abdulrahman Aljamal
    • 1
  • Mohammed Aljamal
    • 1
  • Sanjeev Mulekar
    • 1
  • Aleissa Ahmed
    • 1
  1. 1.The National Center of Vitiligo and PsoriasisRiyadhKingdom of Saudi Arabia

Personalised recommendations